Gefitinib Usage and Outcomes in Routine Treatment

A Multicentre, Retrospective Chart Review Study to Characterise Gefitinib Usage and Outcomes in Routine Treatment

The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population

A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes in routine treatment

Inclusion Criteria:

• Patients who received gefitinib first line in the UK Single Payment Access (SPA) scheme
• Locally advanced or metastatic EGFR mutation positive NSCLC
• Supplied with first pack of gefitinib prior to 1st January 2012

Exclusion Criteria:

• Patient was treated privately (i.e. outside the NHS)
• Gefitinib was second-line therapy following treatment failure on a prior therapy